Tag: University of Sydney News
ROKiT Pharma Pre-clinical Studies Show Tremendous Promise for Naturally Derived Cancer Drug, ROK-001
LOS ANGELES, Calif. /California Newswire/ -- ROKiT Pharma, Inc., a public-benefit corporation dedicated to putting patients first, announced today it is rapidly progressing through final preclinical studies and moving forward with preparation for the initiation of a Phase 1b/2 clinical trial of ROK-001, a potentially low toxicity cancer drug derived from natural ingredients.
